Pharma

Just as it's doing with nearly every facet of society around the world, the COVID-19 crisis will radically transform approaches with patient engagement and pop health. From telemedicine and remote patient monitoring to AI and advanced analytics, healthcare was already in the midst of big changes in how it manages the health of patient populations. Now, in a new era where the pandemic is upending old assumptions, the stakes are even higher. This month, we look at how approaches to treating COVID-19 and other illnesses are shifting in this new era.  

The new tool called, World Without COVID, is aimed at matching potential volunteers to new clinical trials. 

From 2000 to 2017, the number of registered clinical trials featuring CGMs, apps and other connected devices rose at a 34% CAGR, according to new data from Harvard researchers.

The advantages to health and human service delivery in a bot workforce include speed, reliability, consistency and cost-effectiveness. Sound too far-fetched for your management team? We would disagree.  

The test was designed to identify specific antibodies in order to detect if a patient has had coronavirus in the past. 

The startup is working with national emergency services to remotely triage, support and manage infected people in isolation.

German-based Ralf Jahns, MD at Research2Guidance, explains the role of different stakeholders in fighting COVID-19.

The HIMSS Media team gives a recap of recent headlines surrounding the FDA, COVID-19 and new digital health software products.

Also: Providence supporting COVID-19 patients at home with Xealth and Twistle; Lief Therapeutics incorporates DrChrono's Open API.

Dr. Yuri Maricich, chief medical officer at Pear Therapeutics, speaks on his company's experience bringing a digital therapeutic product through the regulator's experimental program for health software.